Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -59.27% is 13% above its 5-year average of -68.15%, near the high end of its 5-year range (-270.72%–-21.73%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.78% above its 12-month average of -88.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -59.27%.
RETURN ON EQUITY (ROE)
-59.27%
RETURN ON EQUITY (ROE) AVG TTM
-88.18%
RETURN ON EQUITY (ROE) AVG 3Y
-133.12%
RETURN ON EQUITY (ROE) AVG 5Y
-68.15%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.78%
CURRENT VS 3Y AVG
+55.47%
CURRENT VS 5Y AVG
+13.03%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-41.09%
vs the sector median at left
Invivyd, Inc.
Market Cap
$237.22M
Return on Equity (ROE)
-59.27%
TTM Avg
-88.18%
3Y Avg
-133.12%
5Y Avg
-68.15%
Market Cap
$237.69M
Return on Equity (ROE)
-31.55%
TTM Avg
-30.05%
3Y Avg
-33.97%
5Y Avg
-37.95%
Market Cap
$236.58M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$236.39M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$235.73M
Return on Equity (ROE)
8.59%
TTM Avg
10.64%
3Y Avg
12.16%
5Y Avg
12.16%
Market Cap
$238.81M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
Market Cap
$235.36M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
Market Cap
$234.54M
Return on Equity (ROE)
-1.67%
TTM Avg
19.58%
3Y Avg
23.42%
5Y Avg
29.49%
Market Cap
$233.46M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $237.22M | -59.27% | -88.18% | -133.12% | -68.15% |
| High Tide Inc. (HITI)vs › | $237.69M | -31.55% | -30.05% | -33.97% | -37.95% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | N/A | -125.28% | -42.20% | -43.41% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.39M | -118.58% | 62.37% | -376.78% | -340.60% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.73M | 8.59% | 10.64% | 12.16% | 12.16% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $238.81M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $235.36M | -43.11% | -35.75% | -28.47% | -12.53% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.54M | -1.67% | 19.58% | 23.42% | 29.49% |
| InflaRx N.V. (IFRX)vs › | $233.46M | -27.27% | -92.43% | -64.95% | -57.80% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | N/A | 35.05% | 64.68% | -167.54% |
ROE
-59.3%
ROA
-49.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -59.27% |
| 2026-03-31 | -38.22% |
| 2025-12-31 | -21.73% |
| 2025-09-30 | -64.32% |
| 2025-06-30 | -257.38% |
| 2025-03-31 | -263.57% |
| 2024-12-31 | -251.60% |
| 2024-09-30 | -270.72% |
| 2024-06-30 | -144.93% |
| 2024-03-31 | -115.87% |
| 2023-12-31 | -111.93% |
| 2023-09-30 | -68.79% |
| 2023-06-30 | -62.23% |
| 2023-03-31 | -53.86% |
| 2022-12-31 | -67.79% |
| 2022-09-30 | -74.13% |
| 2022-06-30 | -71.13% |
| 2022-03-31 | -62.86% |
| 2021-12-31 | -40.64% |
| 2021-09-30 | -32.79% |
